Nutriband Inc Warrant 2021- on Nutriband NTRBW 深 沪
等待开盘 11-06 09:30:00 美东时间
0.55
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.55
- 总市值 0
- 52周最高 2.99
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.1745
- 委 比 0.00%
- 总股本 --
- 历史最高 9.07
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.1745
- 每 手 1
- 风险率 0.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
Nutriband Inc. announced the appointment of Robert J. O'Neill, a former U.S. Navy SEAL and best-selling author, to its Advisory Board. O'Neill, known for his role in the operation that killed Osama bin Laden, brings extensive leadership and resilience expertise. He is also a vocal advocate for veterans' health, particularly psychedelic-assisted therapies, aligning with Nutriband's focus on developing abuse-deterrent fentanyl patches. O'Neill's ex...
09-25 12:00
Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
Nutriband Inc. announced that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026, at 5PM ET, with no extension or repricing. Warrant holders may exercise at the current strike price of $6.43 per share until the expiration date. There are currently 910,904 warrants outstanding, representing $5,856,112 in potential proceeds if fully exercised. Nutriband Inc. is focused on developing transdermal pharmaceutical products, includ...
09-22 12:00
Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
Nutriband Inc. has received a Notice of Publication from the USPTO for trademarks related to its abuse-deterrent fentanyl transdermal system. Once approved, the company plans to submit its commercial brand name to the FDA and other international regulators. The product, based on AVERSA™ technology, aims to prevent abuse and misuse of transdermal fentanyl. It has the potential to achieve peak annual US sales of $80 million to $200 million and addr...
09-08 13:00
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
Nutriband Inc. announced that its CEO, Gareth Sheridan, will present at the 2026 Georgia Life Sciences Summit on August 26. The Summit, held in Sandy Springs, Georgia, highlights the state's leadership in life sciences innovation. Nutriband develops abuse-deterrent transdermal technology, with its AVERSA™ technology aiming to prevent drug abuse while ensuring patient access. The company is focused on creating transdermal pharmaceutical products, ...
08-13 11:00
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Nutriband Inc. and its subsidiary Active Intelligence will showcase their expanding AI wellness product portfolio, including new launches like AI Performance Tape, AI Energy Patches, and AI Sleep, at the upcoming ECRM conference in June 2026. The company plans to meet with buyers from major retailers such as Walmart, Amazon, and Cardinal Health to explore national retail opportunities. Nutriband aims to capitalize on growing demand for wellness, ...
05-15 11:00
Nutriband Selects Commercial Brand Name For Abuse-Deterrent Fentanyl Patch; Prepares FDA And Global Trademark Submissions
Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA for approval per FDA Guidance.Nutriband partnered with Brand
03-31 04:18
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband Inc. has chosen a global commercial brand name for its abuse-deterrent fentanyl transdermal system and will submit it to the FDA and other regulatory agencies for approval. The company partnered with Brand Institute, Inc., a leader in pharmaceutical brand name development, to ensure the name is safe, unique, and compliant with regulations. The product uses Nutriband’s AVERSA™ technology, designed to prevent abuse and misuse of transderm...
03-30 20:05
Nutriband Gets Approval To Sell Kinesiology Tapes In Costa Rica
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that The Costa Rica Ministry of Health has approved the Company's line of Kinesiology Tapes for import and Sale. Innomedica CCB, the company's exclusive
03-18 19:08
Nutriband Strikes Distribution Deal With Innomedica For AVERSA Fentanyl
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products
02-17 20:30
Nutriband CEO Publishes Letter to Shareholders
Nutriband Inc. reported on 2025 achievements including advancing their AVERSA™ Fentanyl patch towards commercialization, securing patents, and enhancing shareholder value through strategic moves like selling a subsidiary and issuing preferred stock dividends. The company also joined four prominent indexes and anticipates reduced stock volatility as warrants from their 2021 IPO expire in 2026. AVERSA™ aims to be the world's first abuse-deterrent o...
2025-12-31 12:00
